Search

Now showing items 1-10 of 31

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Coyle, Peter; ... more authors ... less authors ( Springer , 2022 , Article)

SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold ...

One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar

Benslimane, Fatiha M; Al Khatib, Hebah A; Al-Jamal, Ola; Albatesh, Dana; Boughattas, Sonia; ... more authors ... less authors ( Frontiers , 2021 , Article)

Qatar, a country with a strong health system and a diverse population consisting mainly of expatriate residents, has experienced two large waves of COVID-19 outbreak. In this study, we report on 2634 SARS-CoV-2 whole-genome ...

Metabolic Signatures of Type 2 Diabetes Mellitus and Hypertension in COVID-19 Patients With Different Disease Severity.

Elrayess, Mohamed A; Cyprian, Farhan S; Abdallah, Abdallah M; Emara, Mohamed M; Diboun, Ilhame; ... more authors ... less authors ( Frontiers Media , 2022 , Article)

Increased COVID-19 disease severity is higher among patients with type 2 diabetes mellitus and hypertension. However, the metabolic pathways underlying this association are not fully characterized. This study aims to ...

Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.

Al-Sadeq, Duaa W; Shurrab, Farah M; Ismail, Ahmed; Amanullah, Fathima Humaira; Thomas, Swapna; ... more authors ... less authors ( Oxford University Press , 2021 , Article)

Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA ...

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ... less authors ( Oxford Academic , 2021 , Article)

Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to ...

Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience

Bsat, Raghid; Chemaitelly, Hiam; Coyle, Peter; Tang, Patrick; Hasan, Mohammad R; ... more authors ... less authors ( International Society of Global Health , 2022 , Article)

Background: The effective reproduction number, Rt, is a tool to track and understand epidemic dynamics. This investigation of Rt estimations was conducted to guide the national COVID-19 response in Qatar, from the onset ...

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...

Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2 IgG antibodies using advanced detection assays.

Shurrab, Farah M; Al-Sadeq, Duaa W; Amanullah, Fatima Humaira; Al-Absi, Enas S; Qotba, Hamda; ... more authors ... less authors ( Karger , 2022 , Report)

Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point of care (POC) rapid testing kits. However, some rapid ...

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.

Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Nature Research , 2022 , Article)

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...